Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis

hager omar mohammed siddik

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Other: pharmaceutical care services

Study type: Observational

Funder types: Other

Identifiers

NCT03743181

156

Details and patient eligibility

About

Enrolment of clinical pharmacy services in RA patients as a part of health care system has been investigated at many studies but not investigated in active RA patients before. This study aimed to detect drug therapy-related problems (DTRPs) in active rheumatoid arthritis (RA) patients and Investigate the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life (QoL). Methods:Prospective, randomized controlled study to be carried out at rheumatology outpatient clinic, Ain Shams University Hospitals on 50 patients with active RA for 6 months.determine if any drug therapy problems are present.Develop a plan of care that includes interventions to resolve drug therapy problems, achieve goals of therapy, and prevent drug therapy problems. questionnaires was used to measure functional status in RA patients using health assessment questionnaire (HAQ) and assess self-reported quality of life in patients with (RA) using rheumatoid arthritis quality of life questionnaire (RAQOL) and measure adherence using the 4-item Morisky Green Levine Medication Adherence Scale and Disease Activity Score-28 was used as an objective method to assess RA disease activity.

Enrollment: 54 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 18-60 years old
• fulfillment of the American College of Rheumatology /European league against rheumatism (2010 ACR/EULAR ) diagnostic criteria for RA.
• patients with active RA(defined by DAS28 score < 5.1)

Exclusion criteria

• Patients with cognitive impairment.
• The presence of hepatic or renal disease.
• The presence of other rheumatic and connective tissue disorders.

Trial design

54 participants in 2 patient groups

intervention

Description:

will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.

Treatment:

Other: pharmaceutical care services

control

Description:

will received standard care by physician in attendance